Subscribe
Close
  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Renew

RoosterBio Expands Operations in Frederick, Maryland

02/21/2019
RoosterBio, Inc, a privately held regenerative medicine manufacturing platform technology company, plans to expand the company’s footprint in Frederick, Maryland.

“Hundreds of researchers and scientists around the world have used RoosterBio’s adult human mesenchymal stem/stromal cell (hMSCs) products to streamline their product development efforts in the regenerative medicine field, resulting in strong growth for our company,” said RoosterBio CEO Margot S. Connor.

“The additional expansion space in the building we already occupy at The Offices at Westview will better accommodate our growing staff and support our company’s vision,” Connor said.

RoosterBio said it has been actively shaping the new field of Regenerative Medicine Manufacturing with a diverse team of technology disruptors and thought leaders.

The “off-the-shelf” cell banks and bioprocess media products that RoosterBio has commercialized are designed to remove years of time, and millions of dollars, from traditional mesenchymal cell therapeutic product development efforts, company officials said.

In 2018, RoosterBio launched its first line of cGMP-grade hMSC products that are capable of being directly used as starting materials within clinical manufacturing processes. As a premier cell manufacturing platform technology provider with over 50 products available and six additional product launches planned for 2019, RoosterBio said it aims to have the same impact on the emerging stem cell therapy & regenerative medicine fields that Intel had on the computer industry.

Founded in 2013, RoosterBio, Inc. launched operations inside of the Frederick Innovative Technology Center, Inc incubator with five people. In February 2018, the company held a ribbon cutting for their custom-built 14,000 square foot facility designed to accommodate innovation in scale up of mesenchymal cell manufacturing, research and development. In January 2019, the company grew to more than 40 employees and plans to double again in the next 18-24 months.

Share

Exclusive Research